Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.
According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.
The Lonza Board of Directors also announced that Albert M. Baehny, Chairman of the Board, will assume the additional responsibility as CEO ad interim until a permanent successor is appointed.
Baehny had already led the Group on an interim basis in 2020 after then-CEO Marc Funk left the Swiss chemical and biotech group in January 2020 after less than a year in office.
Ruffieux has been CEO since November 2020 and was previously Head of Global Pharma Technical Operations at Roche.
The medium-term strategy and outlook will be discussed in detail at the Capital Markets Day in Visp on October 17, 2023. At the end of July, Lonza reported sales of CHF 3.1 billion and sales growth of 3.2% (5.6% on a constant currency basis) for the first half of 2023, representing underlying sales growth of approximately 10%. CHF 922 million core EBITDA resulted in a margin of 30%.
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.